EP0037814A1 - Fibrin-antibiotikum-gel zur behandlung des infizierten knochens und verfahren zu seiner herstellung - Google Patents

Fibrin-antibiotikum-gel zur behandlung des infizierten knochens und verfahren zu seiner herstellung

Info

Publication number
EP0037814A1
EP0037814A1 EP80901723A EP80901723A EP0037814A1 EP 0037814 A1 EP0037814 A1 EP 0037814A1 EP 80901723 A EP80901723 A EP 80901723A EP 80901723 A EP80901723 A EP 80901723A EP 0037814 A1 EP0037814 A1 EP 0037814A1
Authority
EP
European Patent Office
Prior art keywords
antibiotic
fibrin
bone
thrombin
gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP80901723A
Other languages
German (de)
English (en)
French (fr)
Inventor
Arnim Braun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of EP0037814A1 publication Critical patent/EP0037814A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0042—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A61L24/0031—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/225—Fibrin; Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
    • A61F2310/00377—Fibrin

Definitions

  • Fibrin antibiotic gel for the treatment of infected bone and process for its preparation
  • the invention relates to a fibrin antibiotic gel for the treatment of infected, in particular staphylococcal, infected bone and a method for its production.
  • PMMA polymethyl methacrylate
  • the invention accordingly relates to a fibrin antibiotic gel for the treatment of infected bone with a content of fibrinogen, a thrombin-containing solution enriched with calcium ions and an antibiotic from the group of the aminoglycosides, characterized in that it is an antibiotic tobramycin, gentamycin and / or one of their physiologically acceptable salts.
  • the sulfates are particularly suitable as physiologically acceptable salts. All components of the gel are expediently used in the form of customary commercial preparations.
  • human fibrinogen in the form of a cryoprecipitate containing about 90 mg of thrombinable protein or as a lyophilisate e.g. obtained from human blood from pooled donor plasma.
  • the thrombin-containing solution is expediently prepared by dissolving thrombin (e.g. in the form of a powder) in an aqueous calcium chloride solution.
  • concentration of calcium chloride is preferably about 30 to 50, in particular 40, mmol / l.
  • concentration of thrombin is preferably between about 10 and about 500 NIH units / ml.
  • the antibiotic is expediently used in an amount based on body weight, whereby the maximum daily dose should be observed.
  • concentration of the antibiotic in the gel according to the invention is preferably between about 1 and about 10, in particular between 2 and 5 percent by weight.
  • the gel can be prepared by mixing fibrinogen with an antibiotic (for example, tobramycin sulfate or gentamycin sulfate, each about 5 mg / kg body weight) under sterile conditions and then adding the calcium ion-enriched thrombin-containing solution to polymerize the fibrinogen to fibrin.
  • the gel is preferably produced extracorporeally, ie before it is actually used in the bone cavity.
  • the clotting time depends on the thrombin concentration.
  • the plastic deformability of the resulting clot can be maintained for a period of 1/2 to 1 minute if a thrombin concentration of about 150 NIH units per ml is used.
  • the flow properties of the gel are determined by lower thrombin concentration (10-15 NIH units / ml). Maintained much longer (up to about 3 minutes). Fibrin coagulation is slowed down and the tensile strength of the polymer is increased.
  • the fibrin antibiotic gel with primary cancellous bone plastic not only controls the infection, but also improves the osteogenic potency of the biological implant.
  • Fibrin glue (commercial preparation) is produced from human donor plasma by cold precipitation. For storage, the finished product is deep-frozen and stored at -18 ° C or colder. 1 ml of the solution contains an average of 90 mg of thrombinable protein. The total protein content of the solution is about 10%. In addition to the precipitable fibrinogen, 1 ml of fibrin glue contains 5 - 12% cold-insoluble globulins, a maximum of 5% albumin and about 10 units of factor XIII, as well as traces of plasminogen and coagulation factors of the intrinsic system. The cryopreserved human fibrinogen is thawed at room temperature about 20-30 minutes before its intended use. The viscosity of the preparation decreases with increasing temperature.
  • 3000 NIH units of thrombin dry substance (commercial preparation) are dissolved in 20 ml of an aqueous calcium chloride solution which contains 35 mmol / 1 CaCl 2 .
  • the distal femoral metaphysis was exposed from the side.
  • the corticalis was perforated to a size of 4 x 8 mm with a drill and milling machine and spongy bones were milled out, so that the defect could be filled with approx. 0.5 ml.
  • the marrow was tamped with bone wax for hemostasis.
  • a 4 x 4 x 1 mm collagen fleece was inoculated with 0.05 ml staphylococcal suspension and the bone cavity was contaminated with it. This corresponds to a germ density of 0.5 - 2 x 10 7 colonies.
  • the bone defect was closed in group A with the fibrin-antibiotic gel and in group B with fibrin.
  • group A With good plastic deformability during the polymerization, the distal femoral metaphysis was included in group A. Fill in 0.45 ml fibrin antibiotic gel and compress the fibrin clot over the corticalis window manually for 2 minutes.
  • group B control group
  • 0.1 ml of tobramycin-containing solution was replaced by 0.1 ml of distilled water, so that 0.25 ml of fibrinogen was coagulated by 0.2 ml of thrombin-containing solution.
  • a coagulase-positive, tobramycin-sensitive (MIC ⁇ 0.125 mcg / ml) Staphylococcus aureus isolated from a wound swab from the Orthopedic University Clinic in Heidelberg was used Cultivated 37 ° C, washed off with sterile physiological saline and the bacterial wash-off by turbidity comparison (tube no. 1 of the barium sulfate turbidity series after
  • McFarland to a germ density of approx. 3 x 10 8 germs / ml.
  • the exact number of bacteria (colony-forming units) of the suspension was determined using the plate casting method at the time of application to the animal.
  • a nutrient agar of the following composition was used as the bacterial counting storage (each gram per 1000 ml water):
  • Meat extract 3 Witte Peptone 5, sodium chloride 5, agar 12; pH 7.2.
  • smears from the medullary canal and extra-articular tissue were taken with sterile cotton swabs and each in 0.2% glucose broth and on agar plates (10% mutton blood addition). After an incubation time of 18-24 hours at 37 C, the growth media were checked for growth and incubated for a further 24 hours if there was no turbidity or colony formation. The material was described as sterile if no growth had been shown up to this point. The grown staphylococci were identified by the microscopic preparation, shape and color of the colonies, hemolysis like and detection of the bound coagulase (clumping factor).
  • the pieces of bone taken from the section of the test animals were fixed in 4% neutral, buffered formalin and then carefully decalcified.
  • the decalcifying solution consisted of 200 g of ethylenediaminetetraacetic acid tetrasodium salt, made up to 1000 ml with water and adjusted to pH 7.0-7.2 with citric acid. After decalcification, the samples were embedded in paraffin in the usual way. 3 - 5 u thick layers were stained with hematoxylin-eosin, van Gieson, Di PAS, Giemsa, Ladewig and according to the Weigert's method of presentation of fibrin.
  • the test animals were sacrificed on the 7th postoperative day and the findings were evaluated macroscopically, bacteriologically and histomorphologically. Of the animals in control group B, 15 died of sepsis between the 2nd and 7th day. The decrease in body weight in this group averaged 530 g. In the rabbits (group A) treated with fibrin tobramycin, no animal died from the consequences of an infection. The body weight had only decreased by 136 g on average. I. Macroscopic finding
  • a swab was taken intramedullarily from the surgical area both in the periarticular soft tissue and in the distal femur for bacteriological examination.
  • the smears were sterile in 27 animals and infected in 3 animals. There were found once subcutaneously, once intraosseously and once subcutaneously and intraosseously staphylococci.
  • group B all smears were staphylococcal infected.
  • the test group and control group thus differ with regard to the treatment procedure with an error probability of at most 1%.
  • the local use of Tobra mycin in the fibrin antibiotic gel can be regarded as exceptionally effective according to this statistical statement.
  • the histological examination revealed non-specific inflammation in all animals in the operated area. According to the choice of the pathogen, it was a purulent inflammation, which, however, occurred in different degrees of severity. In group A animals, on average, inflammation was far less severe. An extensive fibrin residue was typically detected in this group. A granulation tissue had already developed around it, which was also permeated with granulocytes and some macrophages. In some cases, newly formed bone trabeculae made of braided bone could be detected. As a rule, the infected area was enclosed by this granulation tissue, the distal epiphyseal joint undamaged, so that one could speak of a localized osteomyelitic process.
  • Example 3 The procedure is analogous to Example 1, but the tobramycin sulfate is replaced by 15 mg of gentamycin sulfate and comparable results are obtained.
  • Example 3 The procedure is analogous to Example 1, but the tobramycin sulfate is replaced by 15 mg of gentamycin sulfate and comparable results are obtained.
  • the application set contains the following individual components:
  • the application set contains the following individual components:

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Materials Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP80901723A 1979-08-31 1981-03-09 Fibrin-antibiotikum-gel zur behandlung des infizierten knochens und verfahren zu seiner herstellung Withdrawn EP0037814A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2935194 1979-08-31
DE2935194 1979-08-31

Publications (1)

Publication Number Publication Date
EP0037814A1 true EP0037814A1 (de) 1981-10-21

Family

ID=6079722

Family Applications (1)

Application Number Title Priority Date Filing Date
EP80901723A Withdrawn EP0037814A1 (de) 1979-08-31 1981-03-09 Fibrin-antibiotikum-gel zur behandlung des infizierten knochens und verfahren zu seiner herstellung

Country Status (3)

Country Link
EP (1) EP0037814A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS56501129A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1981000516A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT369990B (de) * 1981-07-28 1983-02-25 Immuno Ag Verfahren zur herstellung eines gewebeklebstoffes
US6197325B1 (en) * 1990-11-27 2001-03-06 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US7229959B1 (en) 1990-11-27 2007-06-12 The American National Red Cross Supplemented fibrin matrix delivery systems
US6117425A (en) * 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
US6559119B1 (en) 1990-11-27 2003-05-06 Loyola University Of Chicago Method of preparing a tissue sealant-treated biomedical material
US6762336B1 (en) 1998-01-19 2004-07-13 The American National Red Cross Hemostatic sandwich bandage
US6921532B1 (en) 2000-06-22 2005-07-26 Spinal Restoration, Inc. Biological Bioadhesive composition and methods of preparation and use
EP1296724A1 (en) 2000-06-22 2003-04-02 Sam L. Austin Bioadhesive composition and methods of preparation and use
US8293530B2 (en) 2006-10-17 2012-10-23 Carnegie Mellon University Method and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
US8529956B2 (en) 2002-03-18 2013-09-10 Carnell Therapeutics Corporation Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
CA2498212C (en) 2002-09-10 2012-07-17 American National Red Cross Multi-layered hemostatic dressing comprising thrombin and fibrinogen
US8419722B2 (en) 2004-10-29 2013-04-16 Spinal Restoration, Inc. Apparatus and method for injection of fibrin sealant in spinal applications
US8403923B2 (en) 2004-10-29 2013-03-26 Spinal Restoration, Inc. Injection of fibrin sealant in the absence of corticosteroids in spinal applications
US8206448B2 (en) 2004-10-29 2012-06-26 Spinal Restoration, Inc. Injection of fibrin sealant using reconstituted components in spinal applications
US8124075B2 (en) 2004-07-16 2012-02-28 Spinal Restoration, Inc. Enhanced biological autologous tissue adhesive composition and methods of preparation and use
US7597687B2 (en) 2004-10-29 2009-10-06 Spinal Restoration, Inc. Injection of fibrin sealant including an anesthetic in spinal applications
US8529959B2 (en) 2006-10-17 2013-09-10 Carmell Therapeutics Corporation Methods and apparatus for manufacturing plasma based plastics and bioplastics produced therefrom
WO2009020612A1 (en) 2007-08-06 2009-02-12 Stb Lifesaving Technologies, Inc. Methods and dressing for sealing internal injuries
CN113332229A (zh) * 2021-05-19 2021-09-03 周晓晨 用于清除碎石取石术后残留结石碎块的凝胶组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2385802A (en) * 1942-02-09 1945-10-02 Research Corp Process for the manufacture of plastics
US3723244A (en) * 1971-01-18 1973-03-27 Atomic Energy Commission Fibrous fibrin sheet and method for producing same
DE2511122B2 (de) * 1975-03-14 1977-06-08 Vorprodukt fuer die zubereitung von knochenzement
DE2651441C2 (de) * 1976-11-11 1987-01-08 Merck Patent Gmbh, 6100 Darmstadt Antibioticahaltiges Mittel
GB1584080A (en) * 1977-12-05 1981-02-04 Ethicon Inc Absorbable hemostatic composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8100516A1 *

Also Published As

Publication number Publication date
WO1981000516A1 (en) 1981-03-05
JPS56501129A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1981-08-13

Similar Documents

Publication Publication Date Title
EP0037814A1 (de) Fibrin-antibiotikum-gel zur behandlung des infizierten knochens und verfahren zu seiner herstellung
DE69724243T2 (de) Blutstillender schwamm auf kollagenbasis
DE69433939T2 (de) Hämostatisches pflaster
DE69629010T2 (de) Selbsttragende flächengebilde aus vernetztem fibrin zur hemmung von postoperativen adhäsionen
DE69724257T2 (de) Verwendung von oxydierter zellulose und ihrer komplexen zur behandlung von chronischen wunden
AT412445B (de) Flüssiges collagen-hämostatikum
Itokazu et al. The sustained release of antibiotic from freeze-dried fibrin-antibiotic compound and efficacies in a rat model of osteomyelitis
DE19851334A1 (de) Flexible Wundauflage auf Fibrinbasis und Verfahren zu ihrer Herstellung
EP0068149A2 (de) Fibrinogen-haltiges Trockenpräparat, dessen Herstellung und Verwendung
JP2023022260A (ja) 乾燥インプラント組成物及び注射可能なインプラント水性製剤
WO1998043685A2 (de) Antibiotikumhaltige knochenzementpaste
DE19620117C1 (de) Verfahren zur Herstellung eines calciumsulfathaltigen medizinischen Präparats und calciumsulfathaltiges medizinisches Präparat
EP1275397A2 (de) Arzneimittel zur lokalen Anwendung
EP1837039B1 (de) Verwendung von fibrinogenhaltigem Gewebekleber zur Verhinderung von Gewebsadhäsionen
EP0321442B1 (de) Biologisch resorbierbares Implantationsmaterial sowie Verfahren zur Herstellung desselben
EP2098255B1 (de) Verfahren zur Herstellung von Kollagen-material
EP0365705A1 (de) Biopräparat zur Behandlung von Wunden
DE3409372A1 (de) Material zum vitalisieren von implantatoberflaechen
EP0318801B1 (de) Zubereitungsformen zur Verhinderung von Adhäsionen von Organen und Organteilen
DE2756256A1 (de) Hilfsmittel zum bedecken und/oder ausfuellen von knochendefekten und verfahren zur herstellung desselben
EP0115549A1 (de) Paste zur Blutstillung und temporären Defektüberbrückung bei Knochentrauma
EP0611571B1 (de) Teicoplaninenthaltendes, lokal applizierbares Arzneimittel mit verzögerter Wirkstofffreisetzung
DE102008013091B4 (de) Verfahren zur Herstellung von Kollagen-Material, Kollagen-Material
DE69428020T2 (de) Topische antibakterielle Zusammensetzung
EP1214941A1 (de) Zubereitung zur Bahandlung von flächigen, offenen Wunden

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19810817

AK Designated contracting states

Designated state(s): AT CH DE FR GB NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19830205

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BRAUN, ARNIM